High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification
By LabMedica International staff writers Posted on 19 Aug 2015 |
A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major manufacturer of HTRF reagents.
HTRF involves several carefully selected fluorophores. Fluorescence resonance energy transfer (FRET) partners must fulfill multiple compatibility criteria. First, their emission spectra must show non-overlapping regions in order to be able to measure each partner's fluorescence individually. Second, the FRET quantum yield (i.e., its efficacy) must be as high as possible. Third, fluorescence emission must occur within a region of the spectrum remote from that naturally produced by proteins; in other words, a red-shifted emission is theoretically better in order to avoid medium-intrinsic fluorescence. HTRF uses a combination of several fluorophores forming different FRET systems. HTRF's central element, the energy donor, consists of a rare earth complex in which the lanthanide ion (europium or terbium) is tightly embedded in a macrocycle. This very unique type of structure gives HTRF donors their long-lived fluorescence properties, as well as robustness that enables these molecules to be used in most assay conditions.
In order to broaden HTRF readout capabilities for use in the field of life sciences, Cisbio Bioassays (Codolet, France) has initiated partnerships with several detection system manufacturers. This collaboration has led to high standard reader certification, indicated by an HTRF sticker. This label guarantees that the reader meets the physical specifications for optimal HTRF readout.
Cisbio recently added the BioTek (Winooski, VT, USA) Synergy Neo2 Multi-Mode Reader to the list of instruments with HTRF certification.
The Synergy Neo2 Multi-Mode Reader was designed for speed and ultra-high quality performance. It incorporates BioTek's patented Hybrid technology, which combines independent monochromator-based and filter-based optics in the same instrument. Thus, continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to four photomultiplier tubes provide ultra-fast measurements with high quality results.
Complementing its sophisticated optic systems, the Synergy Neo2 boasts advanced environment controls, including CO2/O2 control and incubation up to 65 degrees Celsius. Variable shaking supports live cell assays, while cell-based detection is optimized with direct bottom illumination.
The instrument package is powered by BioTek's Gen5 Data Analysis Software and has been configured to integrate seamlessly with the optional BioStackNeo plate stacker, which was designed specifically for use with the Synergy Neo2.
Gary Barush, director of marketing and sales at BioTek, said, “For years BioTek has led the evolution of multimode detection. We are proud to introduce this top-of-the-line reader which combines best in class performance in all modes with the speed that customers demand. In addition to being optimized for biochemical assay performance, Synergy Neo2 provides unsurpassed results for cell based assay detection, while its modular configuration makes this new level of performance accessible for many budgets."
Related Links:
Cisbio Bioassays
BioTek
HTRF involves several carefully selected fluorophores. Fluorescence resonance energy transfer (FRET) partners must fulfill multiple compatibility criteria. First, their emission spectra must show non-overlapping regions in order to be able to measure each partner's fluorescence individually. Second, the FRET quantum yield (i.e., its efficacy) must be as high as possible. Third, fluorescence emission must occur within a region of the spectrum remote from that naturally produced by proteins; in other words, a red-shifted emission is theoretically better in order to avoid medium-intrinsic fluorescence. HTRF uses a combination of several fluorophores forming different FRET systems. HTRF's central element, the energy donor, consists of a rare earth complex in which the lanthanide ion (europium or terbium) is tightly embedded in a macrocycle. This very unique type of structure gives HTRF donors their long-lived fluorescence properties, as well as robustness that enables these molecules to be used in most assay conditions.
In order to broaden HTRF readout capabilities for use in the field of life sciences, Cisbio Bioassays (Codolet, France) has initiated partnerships with several detection system manufacturers. This collaboration has led to high standard reader certification, indicated by an HTRF sticker. This label guarantees that the reader meets the physical specifications for optimal HTRF readout.
Cisbio recently added the BioTek (Winooski, VT, USA) Synergy Neo2 Multi-Mode Reader to the list of instruments with HTRF certification.
The Synergy Neo2 Multi-Mode Reader was designed for speed and ultra-high quality performance. It incorporates BioTek's patented Hybrid technology, which combines independent monochromator-based and filter-based optics in the same instrument. Thus, continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to four photomultiplier tubes provide ultra-fast measurements with high quality results.
Complementing its sophisticated optic systems, the Synergy Neo2 boasts advanced environment controls, including CO2/O2 control and incubation up to 65 degrees Celsius. Variable shaking supports live cell assays, while cell-based detection is optimized with direct bottom illumination.
The instrument package is powered by BioTek's Gen5 Data Analysis Software and has been configured to integrate seamlessly with the optional BioStackNeo plate stacker, which was designed specifically for use with the Synergy Neo2.
Gary Barush, director of marketing and sales at BioTek, said, “For years BioTek has led the evolution of multimode detection. We are proud to introduce this top-of-the-line reader which combines best in class performance in all modes with the speed that customers demand. In addition to being optimized for biochemical assay performance, Synergy Neo2 provides unsurpassed results for cell based assay detection, while its modular configuration makes this new level of performance accessible for many budgets."
Related Links:
Cisbio Bioassays
BioTek
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples